<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atovaquone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atovaquone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Atovaquone: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8957" href="/d/html/8957.html" rel="external">see "Atovaquone: Drug information"</a> and <a class="drug drug_patient" data-topicid="11067" href="/d/html/11067.html" rel="external">see "Atovaquone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F137522"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Mepron</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865997"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>GLN-Atovaquone;</li>
<li>Mepron</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1045349"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiprotozoal</span></li></ul></div>
<div class="block dop drugH1Div" id="F137540"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7d2193b6-abbd-4d41-a999-707598f75d93">
<i>Pneumocystis jirovecii</i> pneumonia, HIV-exposed/-infected</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>
<i>Pneumocystis jirovecii</i> pneumonia (PCP), HIV-exposed/-infected</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4','lexi-content-ref-HHS.3'])">Ref</a></span>): Limited data available in ages &lt;13 years:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis; primary or secondary:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children<b>: </b>Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">1 to 3 months: 30 mg/kg/day once daily</p>
<p style="text-indent:-2em;margin-left:8em;">4 to 24 months: 45 mg/kg/day once daily</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;24 months: 30 mg/kg/day once daily; maximum daily dose: 1,500 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 1,500 mg once daily</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment; mild to moderate infection: </i>Treatment duration: 21 days</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">1 to 3 months: 30 to 40 mg/kg/day divided once or twice daily</p>
<p style="text-indent:-2em;margin-left:8em;">4 to 24 months: 45 mg/kg/day divided once or twice daily</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;24 months: 30 to 40 mg/kg/day divided once or twice daily; maximum daily dose: 1,500 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:6em;">Adolescent: Oral: 750 mg twice daily</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f6647c6-baf3-4374-975e-418ba5001284">Toxoplasmosis; encephalitis, HIV-exposed/-infected</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxoplasmosis </b>
<i>
<b>(toxoplasma gondii);</b></i>
<b> encephalitis, HIV-exposed/-infected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4','lexi-content-ref-HHS.3'])">Ref</a></span>)</b>
<b>: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary prophylaxis: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">1 to 3 months: 30 mg/kg/day once daily</p>
<p style="text-indent:-2em;margin-left:8em;">4 to 24 months: 45 mg/kg/day once daily; with or without pyrimethamine/leucovorin</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;24 months: 30 mg/kg/day once daily; maximum daily dose: 1,500 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 1,500 mg once daily; with or without pyrimethamine/leucovorin</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment (encephalitis):</i> Adolescents: Oral: 1,500 mg twice daily for at least 6 weeks (longer if extensive disease or incomplete response); use in combination with pyrimethamine/leucovorin or sulfadiazine is preferred</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Secondary prophylaxis/chronic maintenance therapy (suppressive):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">1 to 3 months: 30 mg/kg/day once daily with leucovorin</p>
<p style="text-indent:-2em;margin-left:8em;">4 to 24 months: 45 mg/kg/day once daily; with or without pyrimethamine/leucovorin</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;24 months: 30 mg/kg/day once daily; maximum daily dose: 1,500 mg/<b>day; </b>with leucovorin</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 750 to 1,500 mg twice daily; use in combination with pyrimethamine/leucovorin or sulfadiazine is preferred</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c04f789-5b51-49cc-b68d-d3d58ad6925e">Babesiosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Babesiosis</b>: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17029130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17029130'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Oral: 40 mg/kg/day divided twice daily; maximum daily dose: 1,500 mg/day with azithromycin for 7 to 10 days</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 750 mg twice daily for 7 to 10 days with azithromycin</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51065116"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Adolescents ≥13 years: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). However, atovaquone is not appreciably renally excreted.</p></div>
<div class="block dohp drugH1Div" id="F51065117"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Adolescents ≥13 years: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). Atovaquone undergoes enterohepatic cycling and primarily hepatic excretion. Use caution in patients with severe impairment; monitor closely.</p></div>
<div class="block doa drugH1Div" id="F137526"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8957" href="/d/html/8957.html" rel="external">see "Atovaquone: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c04f789-5b51-49cc-b68d-d3d58ad6925e">Babesiosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Babesiosis (off-label use):</b>
<b>Oral:</b> 750 mg twice daily in combination with azithromycin for 7 to 10 days; a longer duration of ≥6 weeks, including 2 weeks after resolution of parasitemia, may be necessary for patients at high risk of relapse (eg, patients who are highly immunocompromised) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900295','lexi-content-ref-6810084','lexi-content-ref-33501959','lexi-content-ref-11078770','lexi-content-ref-18181735','lexi-content-ref-27115378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900295','lexi-content-ref-6810084','lexi-content-ref-33501959','lexi-content-ref-11078770','lexi-content-ref-18181735','lexi-content-ref-27115378'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d90b72e-8893-4719-a107-be19527d217f">
<i>Pneumocystis jirovecii</i> pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Pneumocystis jirovecii</i> pneumonia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis, patients without HIV (alternative agent):</i>
<b>Oral:</b> 1.5 g once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis (primary and secondary), patients with HIV (alternative agent):</i>
<b>Oral:</b> 1.5 g once daily (as monotherapy or with pyrimethamine and leucovorin). Continue prophylaxis following initiation of antiretroviral therapy (ART) until CD4 count &gt;200 cells/mm3 for &gt;3 months; some experts discontinue prophylaxis in patients with a CD4 count between 100 to 200 cells/mm3 who are receiving ART and have had an undetectable viral load for ≥3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, mild to moderate disease (alternative agent): </i>
<b>Oral:</b> 750 mg twice daily for 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bcb0d83-61de-4464-9455-4d1401af26c2">Toxoplasmosis encephalitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxoplasmosis encephalitis (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary prophylaxis in patients with HIV:</i>
<b>Oral: </b>1.5 g once daily (either as monotherapy or with pyrimethamine plus leucovorin); primary prophylaxis is indicated for Toxoplasma IgG-positive patients with CD4 count &lt;100 cells/mm<sup>3</sup>. Continue primary prophylaxis following initiation of ART until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;3 months; some experts discontinue primary prophylaxis in patients with a CD4 count between 100 to 200 cells/mm<sup>3</sup> who are receiving ART and have had an undetectable viral load for ≥3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i>
<b>Oral: </b>1.5 g twice daily (either with pyrimethamine plus leucovorin or with sulfadiazine); for patients with HIV, monotherapy may be considered if patients are intolerant to combination agents. Duration is for ≥6 weeks (longer if extensive disease or incomplete response) followed by chronic maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900295','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900295','lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Secondary prophylaxis (chronic maintenance):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Patients with HIV: <b>Oral:</b> 750 mg to 1.5 g twice daily (either with pyrimethamine plus leucovorin, or with sulfadiazine, or as monotherapy); may discontinue when asymptomatic and CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;6 months in response to ART (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Solid organ transplant recipients: <b>Oral: </b>750 mg every 6 to 12 hours (either with pyrimethamine plus leucovorin, or with sulfadiazine, or as monotherapy); continue lifelong (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900295']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900295'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990260"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (&lt;1% excreted in the urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (highly protein bound): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.dor'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987428"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Use caution in patients with severe impairment.</p></div>
<div class="block adr drugH1Div" id="F137498"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined. Adverse reaction statistics have been compiled from studies including patients with advanced HIV disease. Consequently, it is difficult to distinguish reactions attributed to atovaquone from those caused by the underlying disease or a combination thereof.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (16% to 31%), insomnia (10% to 19%), depression, pain</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (22% to 46%), pruritus (5% to ≥10%), diaphoresis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (19% to 42%), nausea (21% to 32%), vomiting (14% to 22%), abdominal pain (4% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (18% to 22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (8% to 31%), myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (14% to 25%), rhinitis (5% to 24%), dyspnea (15% to 21%), sinusitis (7% to ≥10%), flu-like symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (14% to 40%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (3% to 8%), anxiety (≤7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia (7% to 10%), hyperglycemia (≤9%), increased amylase (7% to 8%), hypoglycemia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Oral candidiasis (5% to 10%), anorexia (≤7%), dyspepsia (≤5%), constipation (≤3%), dysgeusia (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (4% to 6%), neutropenia (3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (4% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (≤1%), increased serum creatinine (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Acute renal failure, angioedema, constriction of the pharynx, corneal disease (vortex keratopathy), desquamation, erythema multiforme, hepatic failure (rare), hepatitis (rare), hypersensitivity reaction, methemoglobinemia, pancreatitis, Stevens-Johnson syndrome, thrombocytopenia, urticaria</p></div>
<div class="block coi drugH1Div" id="F137509"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to atovaquone or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F137495"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diarrhea/vomiting: Absorption may be decreased in patients who have diarrhea or vomiting.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (eg, angioedema, bronchospasm, throat tightness, urticaria) have occurred.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disorders: Consider parenteral therapy with alternative agents in patients who have difficulty taking atovaquone with food. Gastrointestinal disorders may limit absorption of oral medications; may not achieve adequate plasma levels.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with severe hepatic impairment; rare cases of cholestatic hepatitis, elevated liver function tests, and fatal liver failure have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• <i>Pneumocystis jirovecii</i> pneumonia (PCP): Appropriate use: When used for treatment, has only been indicated in mild to moderate PCP; not studied for use in severe PCP. Atovaquone has less adverse effects than trimethoprim-sulfamethoxazole (TMP-SMX) (the treatment of choice for mild to moderate PCP), although atovaquone is less effective than TMP-SMX (HHS [OI adult 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F137504"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mepron: 750 mg/5 mL (5 mL, 210 mL) [contains benzyl alcohol; citrus flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 750 mg/5 mL (5 mL, 10 mL [DSC], 210 mL)</p></div>
<div class="block geq drugH1Div" id="F137491"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F6884404"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Atovaquone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg/5 mL (per mL): $6.56 - $7.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Mepron Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg/5 mL (per mL): $7.96</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865998"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mepron: 750 mg/5 mL (210 mL) [contains benzyl alcohol, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 750 mg/5 mL (210 mL)</p></div>
<div class="block admp drugH1Div" id="F52612271"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Must administer with food or a high-fat meal. Shake suspension gently before use. Once opened, a foil pouch can be emptied on a dosing spoon, in a cup, or directly into the mouth.</p></div>
<div class="block adm drugH1Div" id="F6265261"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Must administer with food. Shake suspension gently before use. Once opened, a foil pouch can be emptied on a dosing spoon, in a cup, or directly into the mouth.</p></div>
<div class="block sts drugH1Div" id="F137518"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 15°C to 25°C (59°F to 77°F). Do not freeze.</p></div>
<div class="block usep drugH1Div" id="F53565537"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prevention of <i>Pneumocystis jirovecii</i> pneumonia (PCP) and second-line treatment of mild to moderate PCP in patients intolerant of trimethoprim/sulfamethoxazole (TMP/SMX) (All indications: FDA approved in ages ≥13 years and adults)</p></div>
<div class="block cyt drugH1Div" id="F13298792"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F137499"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amodiaquine: May enhance the adverse/toxic effect of Atovaquone. Specifically, the risk for extrapyramidal side effects may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: May decrease the serum concentration of Atovaquone. Management: Consider alternatives to the use of atovaquone with efavirenz when possible.  If this combination must be used, monitor for evidence of reduced atovaquone clinical effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: Atovaquone may increase the serum concentration of Etoposide.  Management: Consider separating the administration of atovaquone and etoposide by at least 1 to 2 days.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: Atovaquone may increase the serum concentration of Etoposide Phosphate.  Management: Consider separating the administration of atovaquone and etoposide by at least 1 to 2 days.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: Atovaquone may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May increase the serum concentration of Atovaquone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May decrease the serum concentration of Atovaquone. Management: Consider alternatives to metoclopramide when possible; atovaquone should only be used with metoclopramide if no other antiemetics are available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Atovaquone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: Atovaquone may decrease the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Atovaquone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: Atovaquone may increase the serum concentration of RifAMPin. RifAMPin may decrease the serum concentration of Atovaquone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease the serum concentration of Atovaquone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracycline (Systemic): May decrease the serum concentration of Atovaquone.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F137519"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Ingestion with a fatty meal increases absorption. Management: Administer with food, preferably high-fat meals (peanuts or ice cream).</p></div>
<div class="block dic drugH1Div" id="F6265260"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Must be taken with food.</p></div>
<div class="block pri drugH1Div" id="F6264005"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Data specific to the use of atovaquone in pregnancy are limited.</p>
<p style="text-indent:0em;margin-top:2em;">Diagnosis and treatment of <i>Pneumocystis jirovecii</i> pneumonia (PCP) in pregnant patients is the same as in nonpregnant patients. Atovaquone may be used as an alternative agent for PCP and <i>Toxoplasma gondii</i> infections when needed in pregnancy (HHS [OI adult 2023]).</p></div>
<div class="block mopp drugH1Div" id="F53565521"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential, liver enzymes, bilirubin, serum electrolytes (Na), SCr, serum amylase</p></div>
<div class="block pha drugH1Div" id="F137494"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits electron transport in mitochondria resulting in the inhibition of key metabolic enzymes responsible for the synthesis of nucleic acids and ATP</p></div>
<div class="block phk drugH1Div" id="F137508"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Enhanced ~2-fold with food</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 0.6 ± 0.17 L/kg; CSF concentration is &lt;1% of the plasma concentration</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Unknown</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Suspension (administered with food): 47% ± 15%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Range: 67 ± 33.4 hours to 77.6 ± 23.1 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (&gt;94% as unchanged drug); urine (&lt;1%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038533"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Wellvone</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Wellvone</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Wellvone</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Atovaquon glenmark | Wellvone</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Wellvone</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Atovacuona Glenmark | Wellvone</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Atovaquone biogaran</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Atovaquone glenmark | Wellvone</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Wellvone</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Samitrel | Samtirel</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Wellvone</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Wellvone</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Atovaquon | Wellvone</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Wellvone</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Wellvone</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Mepron</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Atovaquona kabi | Wellvone</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Atovaquone glenmark | Wellvone</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Wellvone</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8222520">
<a name="8222520"></a>Artymowicz RJ, James VE. Atovaquone: A New Antipneumocystis Agent. <i>Clin Pharm</i>. 1993;12(8):563-570.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/8222520/pubmed" id="8222520" target="_blank">8222520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8520094">
<a name="8520094"></a>Behbahani R, Moshfeghi M, Baxter JD. Therapeutic Approaches for AIDS-Related Toxoplasmosis. <i>Ann Pharmacother</i>. 1995;29(7-8):760-768.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/8520094/pubmed" id="8520094" target="_blank">8520094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Parasites - Babesiosis. <a href="https://www.cdc.gov/parasites/babesiosis/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/babesiosis/health_professionals/index.html</a>. Updated June 16, 2023. Accessed July 7, 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11941551">
<a name="11941551"></a>Chirgwin K, Hafner R, Leport C, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. <i>Clin Infect Dis</i>. 2002;34(9):1243-1250. doi:10.1086/339551<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/11941551/pubmed" id="11941551" target="_blank">11941551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9862944">
<a name="9862944"></a>El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone Compared With Dapsone for the Prevention of <i>Pneumocystis carinii</i> in Patients With HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both. <i>N Engl J Med</i>. 1998;339(26):1889-1895.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/9862944/pubmed" id="9862944" target="_blank">9862944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.dor">
<a name="Expert.dor"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8305784">
<a name="8305784"></a>Haile LG, Flaherty JF. Atovaquone: A Review. <i>Ann Pharmacother</i>. 1993;27(12):1488-1494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/8305784/pubmed" id="8305784" target="_blank">8305784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>HHS. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV- Exposed and HIV-Infected Children: Recommendations From the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Available at: <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/tables-pediatric-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/tables-pediatric-oi.pdf</a>. December 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>HHS. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. 2017. Available at <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9624466">
<a name="9624466"></a>Hughes W, Dorenbaum A, Yogev R, et al. Phase I Safety and Pharmacokinetics Study of Micronized Atovaquone Human Immunodeficiency Virus-Infected Infants and Children. Pediatric AIDS Clinical Trials Group. <i>Antimicrob Agents Chemother</i>. 1998;42(6):1315-1318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/9624466/pubmed" id="9624466" target="_blank">9624466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8479489">
<a name="8479489"></a>Hughes W, Leoung G, Kramer F, et al. Comparison of Atovaquone (566C80) With Trimethoprim-Sulfamethoxazole to Treat <i>Pneumocystis carinii</i> Pneumonia in Patients With AIDS. <i>N Engl J Med</i>. 1993;328(21):1521-1527.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/8479489/pubmed" id="8479489" target="_blank">8479489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8874627">
<a name="8874627"></a>Katlama C, Mouthon B, Gourdon D, et al. Atovaquone as Long-term Suppressive Therapy for Toxoplasmic Encephalitis in Patients With AIDS and Multiple Drug Intolerance. Atovaquone Expanded Access Group. <i>AIDS</i>. 1996;10(10):1107-1112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/8874627/pubmed" id="8874627" target="_blank">8874627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33501959">
<a name="33501959"></a>Krause PJ, Auwaerter PG, Bannuru RR, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 guideline on diagnosis and management of babesiosis. <i>Clin Infect Dis</i>. 2021;72(2):185-189. doi:10.1093/cid/ciab050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/33501959/pubmed" id="33501959" target="_blank">33501959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18181735">
<a name="18181735"></a>Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. <i>Clin Infect Dis</i>. 2008;46(3):370-376. doi:10.1086/525852<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/18181735/pubmed" id="18181735" target="_blank">18181735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11078770">
<a name="11078770"></a>Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. <i>N Engl J Med</i>. 2000;343(20):1454-1458. doi:10.1056/NEJM200011163432004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/11078770/pubmed" id="11078770" target="_blank">11078770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30900295">
<a name="30900295"></a>La Hoz RM, Morris MI; Infectious Diseases Community of Practice of the American Society of Transplantation. Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, Babesia, Acanthamoeba, Balamuthia, and Naegleria in solid organ transplant recipients- guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13546. doi:10.1111/ctr.13546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/30900295/pubmed" id="30900295" target="_blank">30900295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20955469">
<a name="20955469"></a>Martina MN, Cervera C, Esforzado N, et al. Toxoplasma gondii primary infection in renal transplant recipients. Two case reports and literature review. <i>Transpl Int</i>. 2011;24(1):e6-e12. doi:10.1111/j.1432-2277.2010.01173.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/20955469/pubmed" id="20955469" target="_blank">20955469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mepron.1">
<a name="Mepron.1"></a>Mepron (atovaquone) [prescribing information]. Durham, NC: GlaxoSmithKline; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pagano.1">
<a name="Pagano.1"></a>Pagano G, Kennedy W, Weller S, et al, “The Safety and Pharmacokinetics of Atovaquone in Immunocompromised Children,” Abstracts of the IX International Conference on AIDS in Affiliation With the IV STD World Congress: Berlin, 1993, June 6-11; Abs No PO-B10-1455.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27115378">
<a name="27115378"></a>Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. <i>JAMA</i>. 2016;315(16):1767-1777. doi:10.1001/jama.2016.2884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/27115378/pubmed" id="27115378" target="_blank">27115378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7588086">
<a name="7588086"></a>Spencer CM, Goa KL. Atovaquone. A Review of Its Pharmacological Properties and Therapeutic Efficacy in Opportunistic Infections. <i>Drugs</i>. 1995;50(1):176-196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/7588086/pubmed" id="7588086" target="_blank">7588086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9114194">
<a name="9114194"></a>Torres RA, Weinberg W, Stansell J, et al. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group. <i>Clin Infect Dis</i>. 1997;24(3):422-429. doi:10.1093/clinids/24.3.422<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/9114194/pubmed" id="9114194" target="_blank">9114194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Accessed July 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17029130">
<a name="17029130"></a>Wormser GP, Dattwyler RJ, Shapiro ED, et al. The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2006;43(9):1089-1134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-pediatric-drug-information/abstract-text/17029130/pubmed" id="17029130" target="_blank">17029130</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12856 Version 278.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
